Bivalirudin in stable angina and acute coronary syndromes

Thomas A. Mavrakanas, Yiannis S. Chatzizisis

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


A parenteral anticoagulant is indicated in patients with acute coronary syndromes. Which anticoagulant should be preferred in each setting is not clearly established. Bivalirudin administration was considered in acute coronary syndromes after several clinical trials showed decreased bleeding risk with its use compared with the association of unfractionated heparin (UFH) with glycoprotein IIb/IIIa inhibitors (GPIs). Most recent data demonstrate that the bleeding benefit identified in the previous studies was not due to bivalirudin's properties but to higher bleeding incidence in the comparator arm due to the disproportional use of GPIs with heparin. This paper reviews clinical evidence on bivalirudin as anticoagulant in stable angina and acute coronary syndromes.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalPharmacology and Therapeutics
StatePublished - Jun 29 2015
Externally publishedYes


  • Acute coronary syndrome
  • Angina
  • Bivalirudin
  • Heparin
  • Non-ST-elevation myocardial infarction
  • ST-elevation myocardial infarction

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Bivalirudin in stable angina and acute coronary syndromes'. Together they form a unique fingerprint.

Cite this